Cosmos Health forecasts 2029 revenue of $200.6 million

Cosmos Health

COSM

0.00

Cosmos Health issued 2026–2029 guidance, targeting 2029 revenue of USD 200.6 million, gross profit of USD 71.2 million, adjusted EBITDA of USD 44.2 million.
Gross margin forecast to widen to 35.5% by 2029 from 12.1% in 2025 as mix shifts toward proprietary products.
Net income expected to turn positive in 2027; 2029 net income seen at USD 31 million, non-diluted EPS at USD 0.73.
Operating cash flow projected to flip positive in 2027 at USD 11.9 million; cash and equivalents seen rising to USD 62.9 million by 2029.
Forecast built on 2025 revenue of USD 65.3 million, up 20% year over year; 2026 revenue expected at USD 90.5 million.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cosmos Health Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605260934PRIMZONEFULLFEED9726485) on May 26, 2026, and is solely responsible for the information contained therein.

More This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.